engineered regulatory T cell therapy (Bristol Myers Squibb/Gentibio)

N/A

Report date: 2025/06/11 10:55:21

Base Information

Drug Nameengineered regulatory T cell therapy (Bristol Myers Squibb/Gentibio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionRegulatory T-lymphocytes stimulantsImmunosuppressants
TargetsNot applicable
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGentiBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesGentiBio IncBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A